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Abstract 23 
Airway mucus hypersecretion contributes to the morbidity and mortality in patients with 24 
chronic inflammatory lung diseases. Reducing mucus production is crucial for improving 25 
patients’ quality of life. The transcription factor SAM-pointed domain–containing Ets-like 26 
factor (SPDEF) plays a critical role in the regulation of mucus production, and therefore 27 
represents a potential therapeutic target. This study aims to reduce lung epithelial mucus 28 
production by targeted silencing SPDEF using the novel strategy epigenetic editing.  29 
Zinc fingers and CRISPR/dCas platforms were engineered to target repressors (KRAB, DNA 30 
methyltransferases, histone methyltransferases) to the SPDEF promoter.  31 
All constructs were able to effectively suppress both SPDEF mRNA and protein expression, 32 
which was accompanied by inhibition of downstream mucus-related genes (Anterior 33 
gradient 2 (AGR2), Mucin 5AC (MUC5AC)). For the histone methyltransferase G9A, and not 34 
its mutant nor other effectors, the obtained silencing was mitotically stable.  35 
These results indicate efficient SPDEF silencing and down regulation of mucus related gene 36 
expression by epigenetic editing, in human lung epithelial cells. This opens avenues for 37 
epigenetic editing as a novel therapeutic strategy to induce long-lasting mucus inhibition. 38 
  39 
Introduction 40 
Airway epithelial mucus secretion and mucociliary clearance plays a key role in protective 41 
innate immune responses against inhaled noxious particles and microorganisms. However, 42 
excessive mucus production and secretion contributes to the pathogenesis of several 43 
chronic inflammatory lung diseases such as asthma and chronic obstructive pulmonary 44 
disease (COPD) (9, 11, 27). In patients with asthma and COPD, mucus hypersecretion is 45 
associated with cough and sputum production, respiratory infections, accelerated lung 46 
function decline, exacerbations and mortality (23, 34). Therefore, targeted treatment of 47 
pathologic airway mucus secretion is expected to not only improve symptoms of cough and 48 
dyspnea, but also decrease the frequency of disease-related exacerbations and decelerates 49 
the disease progression. In the past few years, in preclinical models relevant to COPD, 50 
several drugs were shown to reduce mucus hypersecretion (21). However, none of these 51 
drugs targeted the mucus producing cell itself.  52 
Airway mucus contains mostly water and secreted mucins that contribute to the viscosity 53 
and elasticity of mucus gels. Mucin 5AC (MUC5AC) is the major secreted mucin, which is 54 
mainly produced by goblet cells in the airway epithelium. In chronic respiratory diseases, 55 
mucus hypersecretion is highly associated with increased numbers of goblet cells, as well as 56 
up regulated levels of mucin synthesis and secretion (9). SAM pointed domain-containing 57 
Ets transcription factor (SPDEF) has been reported to be a core transcription factor (TF) that, 58 
within a large network of genes, controls mucus production and secretion (6, 22, 35). In 59 
lung, SPDEF is selectively expressed in goblet cells lining the airways of patients with chronic 60 
lung disease (6) and mice exposed to allergens (25). In mice, the absence of SPDEF was 61 
shown to protect from goblet cell development after allergen exposure (6, 26). Moreover, 62 
knockdown of SPDEF with small interfering RNA (siRNA) was found to significantly reduce 63 
the expression of IL-13-induced MUC5AC expression and Anterior gradient 2 (AGR2) 64 
expression, which encodes a potential chaperone required for mucin packaging, in the 65 
human bronchial epithelial cell line 16HBE (36). These observations suggest that SPDEF 66 
could be a potential therapeutic target of airway mucus hypersecretion. In this study we set 67 
out to silence SPDEF expression by epigenetic editing. Epigenetic editing is a novel approach 68 
to modulate epigenetic states locally by targeting an epigenetic enzyme to the locus of 69 
interest via DNA-targeting systems, such as zinc fingers (ZFs), transcription activator-like 70 
effectors (TALEs), or clustered regularly interspaced short palindromic repeats (CRISPRs) (5, 71 
8, 17, 33). Compared to artificial transcription factors (ATFs), which exploit programmable 72 
DNA-binding platforms to target transcriptional activators or repressors with no catalytic 73 
domain (such as super KRAB Domain, SKD), epigenetic editing has the promise to induce 74 
stable and inheritable gene modulation (4, 31). In this study, we provide proof-of-concept 75 
that SPDEF provides a promising target for epigenetic editing to prevent epithelial MUC5AC 76 
expression. 77 
 78 
Materials and Methods 79 
Cell culture 80 
Human bronchial epithelial 16HBE 14o- (16HBE) and BEAS-2B, mucoepidermoid carcinoma 81 
NCI-H292 and type II alveolar carcinoma A549 cell lines were cultured as previously 82 
described (15). The human embryonic kidney HEK293T cell line (obtained from American 83 
Type Culture Collection (ATCC)) and the breast cancer cell line MCF7 (obtained from ATCC: 84 
HTB-22) were cultured in Dulbecco's modified Eagle medium (Biowhittaker, Verviers, 85 
Belgium). All culture media were supplemented with 2 mmol/L L-glutamine, 50 µg/mL 86 
gentamicin, and 10% FBS (Biowhittaker).  87 
 88 
Plasmids Constructs 89 
Four 18-bp zinc finger (ZF) protein target sites were selected within the SPDEF promoter 90 
using the website www.zincfingertools.org., as previously described (16). The target 91 
sequences are shown in Fig. 2a. The DNA sequences encoding the ZFs were synthesized by 92 
Bio Basic Canada. The fragments encoding the ZFs were digested with BamHI/ NheI 93 
restriction enzymes (Thermo Fisher Scientific, Carlsbad, USA) and cloned into a SKD-NLS-ZF-94 
TRI FLAG backbone, which encodes SKD, a triple-FLAG tag and a nuclear localization signal 95 
(NLS) or a ZF- NLS-VP64-TRI FLAG backbone, which encodes a tetramer of Herpes Simplex 96 
Virus Viral Protein 16 (VP64). Then the SKD-NLS-ZF SPDEF-TRI FLAG fragments and the ZF 97 
SPDEF- NLS-VP64-TRI FLAG were XbaI/ NotI (Thermo Fisher Scientific) digested and 98 
subcloned into a dual promoter lentiviral vector pCDH-EF1-MCS-BGH PCK-GFP-T2A-Puro 99 
(SBI, Cat. #CD550A-1), obtaining constructs CD550A-1 SKD-ZF SPDEF and CD550A-1 ZF 100 
SPDEF-VP64. To obtain the constructs CD550A-1 ZF SPDEF-DNMT3A, the DNMT3A catalytic 101 
domain (kindly provided by Dr. A Jeltsch) was digested out from pMX-ZF-DNMT3A-IRES-GFP 102 
with AscI and PacI, to replace VP64 in the CD550A-1 ZF SPDEF-VP64 vector. Catalytically 103 
mutant of DNMT3A (E74A) (13) was generated by PCR-mediated site directed mutagenesis 104 
on CD550A-1 ZF SPDEF-DNMT3A. To obtain the constructs CD550A-1 ZF SPDEF-G9a and 105 
CD550A-1 ZF SPDEF-G9a W1050A, the G9a catalytic domain and its mutant was digested out 106 
from pMX-E2C-G9a and pMX-E2C-G9a W1050A (10) with AscI and PacI, to replace VP64 in 107 
the CD550A-1 ZF SPDEF-VP64. To construct the CD550A-1 ZF SPDEF without effector 108 
domains (EDs) (SPDEF-NOED), VP64 in the CD550A-1 ZF SPDEF-VP64 was swapped out with 109 
PCR by a multiple cloning site, including restriction sites for AscI, Nsil, BclI, SwaI, and PacI. 110 
The primer information is presented in Table 1. pHAGE EF1α dCas9-VP64 lentiviral construct 111 
was a gift from Rene Maehr & Scot Wolfe (Addgene plasmid # 50918)(18) and the single-112 
chain guide RNA encoding plasmid MLM3636 was a gift from Keith Joung (Addgene plasmid 113 
# 43860). An additional multiple cloning site was added by replacing the VP64 activator with 114 
a sequence containing a MluI restriction site. To obtain the dCas9-epigenetic editor 115 
constructs, the G9a catalytic domain and its mutant, the SUV39h1 catalytic domain (10), and 116 
the catalytic domain of EZH2 (SET) and its mutant were digested out from pMX-ZF-IRES-GFP 117 
with MluI and NotI and subcloned into the empty pHAGE EF1α dCas9. The SKD domain and 118 
the DNMT3A3L catalytic domain and its catalytic mutant (29) were subcloned by amplifying 119 
with primers containing MluI and NotI overhangs. Cloning of guide RNAs (gRNA) was 120 
achieved as previously described (4). Briefly, pairs of DNA oligonucleotides encoding 20 121 
nucleotide gRNA targeting sequences were annealed together to create double-stranded 122 
DNA fragments with 4-bp overhangs. These fragments were ligated into BsmBI-digested 123 
plasmid pMLM3636. Two gRNAs were designed to bind close to the region where ZF3 and 124 
ZF4 bind (Fig. 2A) (GCATGGATCCCCCAGCAAGG and CCTCAGGTTGGGCCTTGCCA, 125 
respectively) and a third gRNA was designed to bind just before transcription start site 126 
(CTGGCCAACTCTTCATCTCG). We verified all constructs by DNA Sanger sequencing 127 
(Baseclear, Leiden, the Netherlands). 128 
 129 
Lentiviral transduction 130 
The lentiviral CD550A-1 constructs, encoding the SPDEF targeting ATFs and epigenetic 131 
editors, were co-transfected with the third generation packaging plasmids pMDLg/pRRE, 132 
pRSV-Rev, pMSV-VSVG into HEK293T cells using the calcium phosphate transfection method 133 
to produce lentiviral particles. The supernatant of HEK293T cells containing virus was 134 
harvested at 48 and 72 hours after transfection. Host A549 cells were seeded in six-well 135 
plates with a density of 80,000 cells per well and transduced on two consecutive days with 136 
the viral supernatant, supplemented with 8 µg/mL polybrene (Sigma-Alrich, Zwijndrecht, 137 
Netherlands). The positive transduced cells were selected in 8 µg/mL puromycin 138 
supplemented medium for four days from 72h after the last transduction and then were 139 
cultured in 1 µg/mL puromycin supplemented medium. Medium was refreshed every 2-3 140 
days. Ten days after the last transduction, cells were harvested for western blot, as well as 141 
RNA and DNA extraction. In the meantime, cells were grown on coverslips for 142 
immunocytochemistry (IHC) and harvested for chromatin immunoprecipitation.  143 
 144 
Generation of MCF7 stable cell lines 145 
The lentiviral pHAGE-EF1α constructs, encoding the dCas9-SKD and epigenetic editors, were 146 
co-transfected with the second generation packaging plasmids psPAX2 and pMD2.G-VSV-G 147 
into HEK293T cells using Lipofectamine LTX-PLUS (Life Technologies) to produce lentiviral 148 
particles. The supernatant of HEK293T cells containing virus was harvested at 48 and 72 149 
hours after transfection. Host MCF7 cells were seeded in six-well plates with a density of 150 
80,000 cells per well and transduced on two consecutive days with the viral supernatant, 151 
supplemented with 8 µg/mL polybrene (Sigma-Alrich, Zwijndrecht, Netherlands). The 152 
positive transduced cells were selected in 8 µg/mL puromycin supplemented medium for 153 
four days from 72h after the last transduction and then were cultured in 1 µg/mL puromycin 154 
supplemented medium.  155 
 156 
gRNA Transfections 157 
To transiently transfect the MLM3636 plasmids containing gRNA constructs, 500,000 of each 158 
stable MCF7 cells were seeded into 6-well plates the day before transfection. For all 159 
experiments, a total of 2 μg of a combination of three gRNA plasmids were cotransfected 160 
using 2 μl PLUS reagent and 4 μl Lipofectamine LTX. The cells were then collected two days 161 
after transfection to isolate RNA and subcultured for additional 12 days. 162 
 163 
Detection of mRNA expression by quantitative real-time PCR 164 
Total RNA was extracted from A549 cells using Trizol reagent (Thermo Fisher Scientific) and 165 
500 ng was used for cDNA synthesis with random primers using Superscript II RNase H - 166 
Reverse transcriptase (Thermo Fisher Scientific). SPDEF, MUC5AC, AGR2 and GAPDH 167 
expression was quantified using qPCR MasterMix Plus (Eurogentec, Belgium) and Taqman 168 
gene expression assays (SPDEF: Hs01026050_m1; MUC5AC: Hs00873651_Mh; AGR2: 169 
Hs00356521_m1; GAPDH: Hs02758991_g1, Thermo Fisher Scientific), mRNA expression of 170 
the fusion proteins (FLAG tag), Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 2 (PLOD2), 171 
Tumor Protein P53 (TP53), RELA Proto-Oncogene, NF-KB Subunit (RELA), Cyclin Dependent 172 
Kinase Inhibitor 1A (CDKN1A) and beta-actin (ACTB) using SYBR® Green PCR Master Mix 173 
(Thermo Fisher Scientific) and gene-specific primers (Table 1) with the LightCycler® 480 174 
Real-Time PCR System (Roche, Basel, Switzerland). Data were analyzed with LightCycler® 175 
480 SW 1.5 software (Roche) and the Fit points method, according to the manufacturer’s 176 
instructions. Expression levels relative to GAPDH were determined with the formula 2-ΔCp 177 
(Cp means crossing points). 178 
 179 
Methylation analysis by pyrosequencing 180 
For DNA methylation analysis of the target regions, genomic DNA was extracted with 181 
chloroform-isopropanol and was bisulfite converted using the EZ DNA Methylation-Kit 182 
(Zymo Research), following the manufacturer’s protocol. Bisulfite-converted DNA was 183 
analyzed by pyrosequencing as previously described (7). The primer information for 184 
pyrosequencing is presented in Table 1. 185 
 186 
Histone modification analysis by chromatin immunoprecipitation and qPCR  187 
 Histone modification induced by ZFs-G9a was analyzed by ChIP as previously described (12). 188 
Briefly, A549 cells were fixed with 1% formaldehyde at 37 °C for 10 min and subsequently 189 
lysed and sonicated using a Bioruptor (Diagenode; High, 30 sec on, 30 sec off, total time 15 190 
minutes). Sheared chromatin was cleared by centrifuge at 4°C (12,000 × g, 10 minutes). Four 191 
microgram of specific antibodies [normal rabbit IgG (abcam, ab46540), H3K9me2 (Milipore, 192 
07-441)] were bound to 50 µl of magnetic Dynabeads (Thermo Fisher Scientific) during 15 193 
minutes incubation, then unbound antibodies were washed-off.  Sheared chromatin 0.25 194 
million cells was added to the antibody precoated magnetic Dynabeads (rotating overnight 195 
at 4°C). Next day, the magnetic Dynabeads were washed three times with PBS, and 196 
chromatin was eluted with 1% (w/v) SDS and 100 mmol/L NaHCO3.  Subsequently, the 197 
elutes were treated with RNase (Roche) for four hours and proteinase K (Roche) for one 198 
hour at 62°C. Then, the column (Qiagen) purified DNA could be analyzed with quantitative 199 
PCR (qPCR). 200 
To assess the induction of histone marks and their spreading, several primer pairs were used 201 
for the SPDEF promoter (Table 1). qPCR was conducted using SYBR Green PCR Master Mix 202 
(Thermo Fisher Scientific) on an LightCycler® 480 Real-Time PCR System (Roche). To 203 
calculate the fold induction/reduction of histone marks we used the formula: Percentage 204 
input = 2(Cpinput-CpChIP) dilution × factor × 100. 205 
 206 
Detection of protein expression by western blot 207 
Transduced A549 cells were lysed in RIPA buffer and proteins were analyzed by standard 208 
western blotting as previously described (7). Then, the blots were incubated with a rabbit 209 
anti-human SPDEF antibody (Santa Cruz, sc-67022), mouse anti-FLAG (Sigma, F3165) and 210 
mouse anti-GAPDH (Santa Cruz, sc-47724) at 4°C, overnight, followed by incubation with an 211 
horseradish peroxidase (HRP)-conjugated secondary goat anti-rabbit and rabbit anti-mouse 212 
antibody (Dako, Glostrup, Denmark). Protein expression was visualized using the Pierce ECL2 213 
chemoluminescence detection kit (Thermo Fisher Scientific) and Gel Doc™ XR+ imaging 214 
systems (Bio-Rad Laboratories). Data were analyzed with Gel Doc™ XR+ Image Lab™ 215 
software.  216 
 217 
Immunocytochemistry  218 
Cells grown on coverslips (Menzel-Gläser, 12 mm in diameter) were washed with PBS and 219 
fixed with 2% (w/v) Paraformaldehyde for 20 min. Cells were stained with primary antibody 220 
against MUC5AC (Abcam, ab3649), followed by HRP-conjugated secondary antibody.  The 221 
peroxidase was visualized by staining with AEC (3-amino-9 ethylcarbazole), followed by 222 
hematoxylin counterstaining. The cover glasses were mounted with Kaiser's glycerol-gelatin 223 
(37°C) and scanned into digital whole slides images using the NanoZoomer series scanning 224 
devices. The assessment of immunochemistry staining intensity was performed 225 
semiquantitatively in a blinded fashion at four to six of x20 magnification fields. MUC5AC 226 
stained cells were categorized as follows: negative (no staining), weak-positive (pink color or 227 
small red dot staining) and strong-positive (red staining and >50% of cell volume). 228 
FLAG tagged proteins were stained with anti-FLAG antibody (Sigma, F3165), followed by 229 
HRP-conjugated secondary antibody and AEC staining. FLAG stained cells were categorized 230 
to negative and positive, and counted in a blinded fashion at four x20 magnification fields. 231 
 232 
Statistics 233 
All transduction experiments were performed at least three times independently. Data were 234 
analyzed using one-way ANOVA followed by Bonferroni's Multiple Comparison Test. Data 235 
were considered to be statistically significant if P<0.05. Data were expressed as mean ± SEM 236 
and calculated using Prism v5.0 (GraphPad software). 237 
 238 
Results 239 
SPDEF down regulation by ATFs and subsequent repression of mucus-related genes 240 
To select a suitable model to study SPDEF down regulation, SPDEF expression was 241 
determined in four different human epithelial cell lines: A549, H292, BEAS-2B and 16HBE. 242 
A549 cells demonstrated the highest expression of SPDEF, both at mRNA level (Fig. 1A) and 243 
at protein level (Fig. 1B). The high expression of SPDEF in A549 and H292 cells was 244 
accompanied by a low degree of DNA methylation at the CpG sites surrounding the 245 
transcription start site (TSS) (A549: CpG sites #13: 2.7%,  CpG sites #14: 4.6%, CpG sites #15: 246 
3.1%; H292: CpG sites #13: 1.9%,  CpG sites #14: 4.2%, CpG sites #15: 3.2%), whereas the 247 
undetectable transcription levels of SPDEF in BEAS-2B and 16HBE were accompanied by a 248 
high level of DNA methylation (BEAS-2B: CpG sites #13: 34.9%,  CpG sites #14: 40.6%, CpG 249 
sites #15: 26.4%; 16HBE: CpG sites #13: 75.9%,  CpG sites #14: 68.5%, CpG sites #15: 41.0%) 250 
(Fig. 1D). Differential expression of MUC5AC was consistent with the observed SPDEF 251 
expression, with the highest MUC5AC expression in A549 cells (Fig. 1C). To explore effective 252 
SPDEF down regulation, we chose the highest SPDEF and MUC5AC expressing cell line 253 
(A549) as a model. 254 
In order to down regulate SPDEF expression, four ZFs were designed to bind 18-base pair 255 
regions in the SPDEF promoter (SPDEF1, SPDEF2, SPDEF3, SPDEF4) and were sub-cloned into 256 
lentiviral constructs containing SKD (Fig. 2A). A549 cells were transduced to express the ATF 257 
using these lentiviral constructs. To enrich for cells expressing the ATF, the lentiviral 258 
transduced cells were positively selected based on puromycin resistance. Correct size of 259 
ATFs was confirmed by western blot (Fig. 2C) and their nuclear location by 260 
immunohistochemical staining (Fig. 3D). FLAG positive cells ranged from 15% (SKD-SPDEF2) 261 
to 64% (SKD-SPDEF3) after the selection with puromycin (Fig 3D). According to the FLAG 262 
staining, SKD-SPDEF1 was expressed to a similar degree as SKD-SPDEF2, and both were 263 
generally lower expressed than SKD-SPDEF3 and SKD-SPDEF4. 264 
 265 
Next, we examined the ability of the four ATFs to down regulate SPDEF mRNA expression in 266 
A549 cells. As shown in Fig. 2B, all four ATFs significantly down regulated SPDEF expression, 267 
demonstrating 70, 97, 93, and 96% respectively down regulation relative to empty vector 268 
control, which was confirmed at the protein level (Fig. 2C). 269 
As SPDEF regulates a network of genes associated with mucus production (2, 20, 28), we 270 
investigated whether the down regulation of SPDEF expression mediated by ATFs indeed 271 
resulted in reduced expression of mucus-related genes. Therefore, the expression level of 272 
two downstream mucus-related genes was investigated in the ATF-expressing A549 cells. 273 
We found that expression of AGR2 was significantly down regulated by SKD-SPDEF2 274 
(90.9%±35.4% repression), SKD-SPDEF3 (79.3%±35.9% repression) and SKD-SPDEF4 275 
(86.2%±35.4% repression) (Fig. 3A). MUC5AC was consistently, yet not significantly, down 276 
regulated in response to SPDEF repression (Fig. 3B). However, MUC5AC immunochemistry 277 
staining on ATF-transduced A549 cells supports successful inhibition at the protein level (Fig. 278 
3C and 3D).  279 
SPDEF silencing by targeted epigenetic editing  280 
In order to achieve the stable gene silencing, we set out to direct DNA methylation onto the 281 
SPDEF promoter. As DNA methylation levels of CpG sites #13 (-3 bp), #14 (-1 bp) and #15 282 
(+40 bp) around the TSS negatively correlated with SPDEF expression, ZF SPDEF3 targeting 283 
location -131 to -114 bp was coupled to the catalytic domain of DNMT3A. To investigate the 284 
induced DNA methylation in the promoter region of SPDEF, 15 CpG sites were screened with 285 
pyrosequencing (Fig. 4). We found that DNA methylation was induced on CpGs sites #14 and 286 
15, and not on CpG sites #1-13. In further experiments, CpG sites #13-15 were analyzed. 287 
SPDEF3-DNMT3A consistently deposited DNA methylation onto two CpG sites (CpG #14: 6.6 288 
± 0.8%; CpG #15: 10.5 ± 1.3%), compared with SPDEF3-NOED (CpG #site 14: 3.9 ± 0.3%; CpG 289 
#15: 5.2 ± 0.8%) (Fig. 5B). To determine whether the observed increase in DNA methylation 290 
was directly caused by the catalytic activity of the DNMT3A enzyme, a catalytic mutant of 291 
DNMT3A (DNMT3A E74A) was constructed and compared to DNMT3A in a separate set of 292 
experiments. No increase in DNA methylation was observed for CpG sites #13-15 in SPDEF3-293 
DNMT3A E74A treated cells (Fig. 5C). To investigate whether the ZF directed DNMT3A was 294 
able to reduce target gene transcription, SPDEF mRNA expression was investigated (Fig. 6A, 295 
left panel). SPDEF3-DNMT3A was able to down regulate SPDEF expression (76.6%±25.5% 296 
repression), which was equally efficient as repression induced by the positive control SKD-297 
SPDEF3 (79.1%±12.7% repression). Interestingly, the construct that lacked the effector 298 
domain, SPDEF3-NOED, also reduced SPDEF expression significantly (72.0%±25.3% 299 
repression). To determine the influence of location, another ZF (SPDEF4: target sequence 300 
+112 to +129) was tested to target DNMT3A to the SPDEF promoter. We found that SPDEF4-301 
DNMT3A was able to better down regulate SPDEF expression (86.9%±12.1% repression) 302 
than control SPDEF4-NOED (46.8%±35.1% SPDEF repression) and the catalytic mutant (Fig. 303 
6A), even though SPDEF4-DNMT3A didn’t induce methylation changes in the investigated 304 
region CpG13-15 (Fig. 5D).  305 
Upon ZFs fused with the histone methyltransferase G9A, again, SPDEF4-G9A was able to 306 
down regulate SPDEF expression equally efficiently as positive control SKD-SPDEF4 and 307 
further repressed SPDEF expression than SPDEF4-NOED (Fig. 6A) However, no difference 308 
was detected between SPDEF4-G9A and its mutant and no H3K9me2 marks were detected 309 
in the examined region (data not shown). The expression of the fusion proteins was 310 
confirmed by the mRNA expression of the FLAG-tag (Fig. 7). The SPDEF4-DNMT3A construct 311 
was not higher expressed than its mutant, indicating that enhanced SPDEF repression of 312 
SPDEF4-DNMT3A compared to its mutant was not because of more occupation of ZFs 313 
SPDEF4 itself. 314 
Down regulation of SPDEF by SPDEF3-DNMT3A, SPDEF4-DNMT3A, SPDEF3-G9A and SPDEF4-315 
G9A was confirmed at the protein level by western blot (Fig. 8). Importantly, expression of 316 
downstream mucus related genes AGR2 and MUC5AC was also down regulated by these 317 
constructs (Fig. 6B and 6C).  318 
Lower number of strong MUC5AC positive cells after targeted silencing SPDEF by 319 
epigenetic editing  320 
The effect of SPDEF inhibition on mucus production was determined by quantification of the 321 
number of MUC5AC positive cells. Transduced A549 cells were seeded on cover slips and 322 
examined by immunochemistry staining. Interestingly, SPDEF silencing was most effective 323 
within the MUC5AC strong positive cell population. Within this population, both SPDEF3-324 
DNMT3A and SPDEF4-G9a treatment resulted in lower numbers of MUC5AC strong positive 325 
(Fig. 9B). To rule out that the effects were caused by a general repressive effect of either 326 
G9A or DNMT3A, we determined expression levels of four irrelevant genes (PLOD2, TP53, 327 
RELA and CDKN1A) and found that none of these demonstrated inhibition of expression (Fig. 328 
10).  329 
 330 
Sustained epigenetic repression of SPDEF by epigenetic editing  331 
To further address the effectiveness and sustainability of gene repression by epigenetic 332 
editing, we decided to use the CRISPR-dCas9 system. We engineered stable MCF7 cell lines, 333 
each one expressing dCas9 fusions either with the transcriptional repressor SKD, several 334 
epigenetic editors or their mutants (G9a and SUV39h1 (for H3K9me), the SET domain of 335 
EZH2 (for H3K27me), or a chimeric DNMT3a-DNMT3L fusion (for DNA methylation(30))). We 336 
designed three gRNAs to bind around the promoter of SPDEF. By transiently transfecting a 337 
mix of the three gRNAs into the stable cell lines, we were able to address the maintenance 338 
of gene repression (Fig. 11A). Gene repression was achieved to similar degrees two days 339 
after transfecting the mix of gRNAs in all stable cell lines. As observed for ZF-fusions, 340 
repression was also observed when using the mutant effector domains (Figs. 11 B-E). 341 
Importantly, for several other genes no such repressive effects by dCas9 without effector 342 
domain have been observed in this stable system (data not shown). While repression by the 343 
transcriptional repressor SKD and most of the epigenetic editors was not maintained, the 344 
repression of SPDEF was sustained when using the G9a effector domain, while the mutant 345 
fusion regained activation.  346 
Discussion 347 
Based on its important role in goblet cell differentiation and mucus production (6, 26), we 348 
reasoned that SPDEF could be a suitable therapeutic target against mucus hypersecretion. In 349 
this study, we were able to silence SPDEF expression in the human alveolar epithelial cell 350 
line A549, using a novel strategy: engineered SPDEF targeting ZF proteins directing 351 
transcriptional repressor (SKD), as well as epigenetic enzymes (DNMT3A and G9A). The 352 
repression of SPDEF was accompanied by lower expression of mucus-related genes MUC5AC 353 
and AGR2, as well as lower numbers of MUC5AC positive cells. 354 
Our data provides an original proof-of-concept study supporting SPDEF as a promising 355 
therapeutic target for inhibiting mucus production, which is amenable to stable repression 356 
with epigenetic editing. As previously reported, knockdown of SPDEF using siRNA was able 357 
to reduce the IL-13-induced expression of MUC5AC and AGR2 in human airway epithelial 358 
16HBE cells (36). The principle of siRNA is to target and degrade mRNA. Because of the 359 
constant production of mRNA, the silencing effect of siRNA is generally transient and it has 360 
to be delivered repeatedly in clinical application. Epigenetic editing would be a superior 361 
strategy because the effect would be sustained after clearance of the drug (hit and run 362 
approach) (8). In order to down-regulate SPDEF expression directly at the transcriptional 363 
level, four sequence-specific ZFs were generated. ZFs were first linked to SKD to test the 364 
functionality of the DNA binding domain because SKD can cause transient gene silencing by 365 
indirectly recruiting chromatin remodelers and histone-modifying enzymes (28, 32). These 366 
four ATFs (ZF-SKD) strongly reduced SPDEF expression and nearly abolished all expression of 367 
SPDEF in A549 cells. More importantly, SPDEF silencing resulted in the additional down 368 
regulation of MUC5AC mRNA and protein expression as well, indicating successful inhibition 369 
of mucin synthesis. 370 
Next, ZFs were fused to catalytic domains of epigenetic enzymes (DNMT3A and G9A), aiming 371 
for longer term gene silencing by changing the epigenetic state of the targeted gene. ZF-372 
targeted DNA methylation was recently successfully used for silencing several cancer-373 
associated genes, including VEGF-A, SOXA2, and EpCAM (24, 28, 29, 31). Here, we took 374 
advantage of this approach by using two different ZFs engineered close to the TSS (SPDEF3 375 
and SPDEF4), to down regulate SPDEF expression. In this area, high expression of SPDEF was 376 
accompanied by lower DNA methylation of CpG sites, particularly those surrounding the 377 
TSS, where DNA methylation is tightly linked to transcriptional silencing (3). The occlusion 378 
binding of TF also explains our observation that ZFs without effector domains effectively 379 
silenced SPDEF expression. We observed similar strong SPDEF repressive effects upon 380 
targeting ZFs without any effector domain as upon targeting ZFs fused with repressor SKDs. 381 
Many factors can explain the repressive effects of the binding of the gene targeting 382 
constructs, like competition with endogenous transcription factors, such as SMAD, or 383 
components of the preinitiation complex formation. Importantly, the effects were also 384 
obtained when targeting CRISPR-dCas9 without an effector by the sgRNAs (20), indicating 385 
that steric hindrance might indeed explain the repressive effect. Since such effects generally 386 
are transient, it is important to assess that addition of domains to the targeting moiety do 387 
not affect inhibition properties. Importantly, the fusion of effector domains to the ZFs did 388 
not hamper the repressive effect of the ZF approach.  389 
As the DNA binding domain by itself, or in fusion with SKD, is not expected to induce any 390 
long-term effects, we next set out to test different epigenetic enzymes (DNMT3A and G9A). 391 
Fusion of epigenetic effector domains with ZFs resulted in the same magnitude of silencing 392 
as the ZF-SKD fusions, indicating that our approach worked as we aimed for. Furthermore, 393 
targeted DNA methylation or histone methylation has the advantage that its effect has the 394 
potential to be permanent (4, 28, 31), albeit the stability and heritability of epigenetic 395 
editing is still controversial (14, 19) and likely depend on the local chromatin modification 396 
state (4).  397 
In an elegant experiment, Bintu and colleagues used an artificial system to compare four 398 
repressive chromatin regulators with distinct chromatin modifications (2): the embryonic 399 
ectoderm development (EED) protein of Polycomb repressive complex 2, which indirectly 400 
catalyzes H3K27 methylation, the KRAB domain, that indirectly promotes H3K9 methylation, 401 
the DNMT3B, that catalyzes DNA methylation and the histone deacetylase 4 (HDAC4) 402 
enzyme. By transiently recruiting each protein, they demonstrate that different types of 403 
repressed chromatin are generally associated with distinct time scales of repression. For this 404 
artificial context, DNA methylation was the modification of choice to achieve long lasting 405 
repression, while histone deacetylation was not sustained. Only few studies so far have 406 
addressed stable silencing of endogenous genes, and controversial effects have been 407 
reported (1, 19, 31). Here, we provide indications that targeting epigenetic effector domains 408 
to SPDEF has the ability to promote sustained gene expression reprogramming. Indeed, we 409 
demonstrated that upon targeting G9A, maintenance of repression was obtained, which 410 
was not observed for the transcriptional repressor SKD, DNA methyltransferase or other 411 
histone modifiers. These differences in maintenance require more thorough investigations, 412 
but likely are due to the particular local chromatin context of the targeted locus, that could 413 
influence the potency and longevity of epigenetic reprogramming. This would also explain 414 
the reported failure of maintenance of induced H3K9methylation effects when studying 415 
VEGF-A repression (19). Combining different effector domains, as we did previously for re-416 
activation of gene expression, might further improve the degree of repression and/or 417 
increase sustainability (4). Indeed, Amabile et al recently demonstrated the importance of 418 
co-targeting KRAB, DNMT3A and DNMT3L in inducing maintained repression for 419 
endogenous genes (1). 420 
One limitation of our study is that functional experiments were conducted in the alveolar 421 
cell line A549. Since we already showed convincing MUC5AC and AGR2 silencing in A549 422 
cells, it will be interesting to investigate whether this effect is also observed within the more 423 
relevant models of mucus hypersecretion in the future, such as using the air-liquid interface 424 
culture of the primary airway epithelial cells from patients with COPD. In addition, before 425 
use in the clinical setting, it is necessary to further evaluate the off-target effects, such as 426 
the ZFs or CRISPR/dCas9 binding specificity and target cell specificity. 427 
In summary, we successfully reduced mucus-related gene expression by targeted silencing 428 
of SPDEF. This new approach (epigenetic editing) has the potential to induce a permanent 429 
anti-mucus effect, which has implications for development of novel therapeutic strategies to 430 
treat patients with chronic mucus hypersecretion in the future. 431 
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Table 1 PCR and sequencing primers 448 
Primer Name Sequence (5'- 3') Application 
SPDEF Pyro-A F GGGTTATGGGAGAGTAAGTTGT PCR and sequencing 
for SPDEF-A 
pyrosequencing SPDEF Pyro-A R [Biotin]TCTATACCCCACAAAATCCTCAT 
SPDEF Pyro-A Seq GTTGTTGGTTGGTTT 
SPDEF Pyro-B/C F GGATTTTGTGGGGTATAGAGAA 
PCR and sequencing 
for SPDEF-B/C 
pyrosequencing SPDEF Pyro-B/C R [Biotin]ATTACTACATAACCACTCAACTCATATT 
SPDEF Pyro-B Seq GGGGTATAGAGAATATAGTT 
SPDEF Pyro-C Seq TTTAGAATTTTAGTTTTGGATTTA 
SPDEF Pyro-D/E F ATGAGTTGAGTGGTTATGTAGTAAT 
PCR and sequencing 
for SPDEF-D/E 
pyrosequencing SPDEF Pyro-D/E R [Biotin]CCAACCCAAAACTACCTACTAAC 
SPDEF Pyro-D Seq AGTGGTTATGTAGTAATTAATG 
SPDEF Pyro-E Seq AATTAGGTTTTGGTTAATTT 
DNMT3a-E74A F CATTGCCTCCGCCGTGTGTGAGG PCR for DNMT3a-E74A 
site mutagenesis 
DNMT3a-E74A R TAGCGGTCCACTTGGATGC 
NOED F CGCGCCATGCATGATCATTTAAATTTAAT PCR for NOED cloning 
NOED R TAAATTTAAATGATCATGCATGG 
SPDEF-ChIP-region 1 F GCATGGGTGGTTCTGGATCT ChIP-qRT-PCR for 
SPDEF region 1 
SPDEF-ChIP-region 1 R GCCAGAGATACGTCGAGTGG 
SPDEF-ChIP-region 2 F GCAGCAACCAATGAACGAGTG ChIP-qRT-PCR for 
SPDEF region 2 
SPDEF-ChIP-region 2 R ATTAACCCTTGCAGGTCTCCC 
SPDEF-ChIP-region 3 F CCAGCACATTCCTGCACTCT ChIP-qRT-PCR for 
SPDEF region 3 
SPDEF-ChIP-region 3 R CAACCTGAGGGGCTTGCAG 
FLAG-F TGAATCGGTAGGAATTCGCGG qRT-PCR for FLAG 
FLAG-R GGGAGGGGCAAACAACAGAT 
GAPDH-F CCACATCGCTCAGACACCAT qRT-PCR for GAPDH 
GAPDH-R GCGCCCAATACGACCAAAT 
ACTB-F CCAACCGCGAGAAGATGA qRT-PCR for ACTB ACTB-R CCAGAGGCGTACAGGGATAG 
RELA-F CGGGATGGCTTCTATGAGG qRT-PCR for RELA RELA-R CTCCAGGTCCCGCTTCTT 
TP53-F GCTCAAGACTGGCGCTAAAA qRT-PCR for TP53 TP53-R GTCACCGTCGTGGAAAGC 
PLOD2-F GGGAGTTCATTGCACCAGTT qRT-PCR for PLOD2 PLOD2-R GAGGACGAAGAGAACGC 
CDKN1A-F TCACTGTCTTGTACCCTTGTGC qRT-PCR for CDKN1A CDKN1A-R GGCGTTTGGAGTGGTAGAAA 
 449 
  450 
Figure legends 451 
Figure 1 Expression of SPDEF (mRNA and protein) is associated with DNA methylation and 452 
MUC5AC expression. Quantification of the mRNA levels of SPDEF (A) and MUC5AC (C) in a 453 
panel of human epithelial cell lines (A549, H292, BEAS-2B, and 16HBE) by qRT-PCR. Dot plots 454 
represent the mean and variation of three independent experiments. (B) Visualization of 455 
SPDEF protein expression (left) and quantification relative to β-ACTIN (right), as conducted 456 
by western blot (n=1). An anti-β-ACTIN antibody was used as a loading control. (D) 457 
Quantitative analysis of the methylation levels of three CpG sites surrounding transcription 458 
start site (TSS) by pyrosequencing. Scatter plots show two independent experiments.  459 
Figure 2 SPDEF-targeted silencing by ATFs in A549 cells. (A) Schematic representations of 460 
the promoter region of the SPDEF gene, outlining the putative binding sites for transcription 461 
factors (STAT6, NKX2-1/NKX3-1, GFI, FOXA1/FOXA2, SMAD) (MatInspector) and the target 462 
sequences of zinc fingers: SPDEF1, SPDEF2, SPDEF3, and SPDEF4. Arrows show the 463 
orientation of the 18-bp binding site in the promoter. Location of ZF was shown relative to 464 
the TSS (+1). The translation start site was shown as ATG (+286). CpGs are indicated as 465 
vertical bars. DNA methylation status of 15 CpGs was analyzed using pyrosequencing for the 466 
indicated areas. Histone modification of H3K9me2 was assessed for the ChIP regions (gray 467 
boxs). (B) Relative SPDEF mRNA expression, normalized to the empty vector, assessed by 468 
quantitative RT-PCR in transduced A549 cells. Data are presented as mean and variation of 469 
three independent experiments. Statistical significance was analyzed using one-way ANOVA 470 
followed by Bonferroni's Multiple Comparison Test (*P<0.05, **P<0.01). (C) SPDEF protein 471 
expression in transduced A549 cells, as conducted by western blot. An anti- Glyceraldehyde 472 
3-phosphate dehydrogenase (GAPDH) antibody was used as a loading control. An anti-FLAG 473 
antibody was used to detect the ATFs, which were designed with a C-terminal 3×FLAG tag. 474 
Blot pictures shown are representative of two independent experiments.  475 
Figure 3 Changes in downstream mucus-related genes after ATFs induced silencing of 476 
SPDEF. (A) MUC5AC and (B) AGR2 mRNA expression were investigated by quantitative RT-477 
PCR. Data are presented as mean and variation of three independent experiments. 478 
Statistical significance was analyzed using one-way ANOVA followed by Bonferroni's 479 
Multiple Comparison Test (*P<0.05, **P<0.01). (C)Quantification of MUC5AC negative, 480 
weak- and strong-positive A549 cells after ATF treatment. Counting of cells was performed 481 
in a blinded fashion. Solid bars, strong positive; shaded bars, weak positive; open bars, 482 
negative. Results represent the average of two independent experiments. (D) 483 
Representative photographs (original magnification, ×20) from immunochemistry staining 484 
for MUC5AC (upper panel) and FLAG (lower panel) in ATFs treated A549 cells. Red-stained 485 
cells are MUC5AC-positive and FLAG-positive respectively. Nuclei were counterstained with 486 
hematoxylin. Scale bar: 100 μm.  487 
Figure 4 Screening of the DNA methylation changes after targeting DNMT3A to SPDEF 488 
promoter. Quantitative analysis is the percentage of methylation for 14 CpG sites in SPDEF 489 
promoter by pyrosequencing in A549 cells treated with mock, empty vector, SPDEF3-NOED 490 
and SPDEF3-DNMT3A in one experiment. (A) CpG sites #1, #3, and #4; (B) CpG sites #5-8; (C) 491 
CpG sites #9-12; (D) CpG sites #13-15. 492 
Figure 5 DNA methylation changes after targeting DNMT3A to SPDEF promoter. (A) 493 
Schematic presentation of SPDEF3-DNMT3A and SPDEF4-DNMT3A, and their binding 494 
location relative to TSS. (B) Quantitative analysis the percentage of methylation for target 495 
CpG sites (#13, #14 and #15) by pyrosequencing in A549 cells treated with mock, empty 496 
vector, SPDEF3-NOED and SPDEF3-DNMT3A (n=4). (C) Relative DNA methylation level of 497 
A549 cells after treatment with SPDEF3-NOED, SPDEF3-DNMT3A and SPDEF3-DNMT3A E74A 498 
normalized to SPDEF3-NOED (n=3). (D) Relative DNA methylation level of A549 cells after 499 
treatment with SPDEF4-NOED, SPDEF4-DNMT3A and SPDEF4-DNMT3A E74A normalized to 500 
SPDEF4-NOED (n=3). Dot plots represent the mean and variation of at least three 501 
independent experiments. Statistical significance was analyzed using one-way ANOVA 502 
followed by Bonferroni’s Multiple Comparison Test (*P<0.05, compared to empty vector; 503 
#P<0.05, ##P<0.01, compared between two indicated columns). 504 
Figure 6 SPDEF and downstream mucus related genes expression changes after targeting 505 
DNMT3A and G9a to SPDEF promoter. A549 cells were treated with ZFs fused with different 506 
effector domains (SKD, DNMT3A, G9a, and the respective mutants DNMT3A E74A and G9a 507 
W1050A). mRNA level of (A) SPDEF, (B) AGR2 and (C) MUC5AC were determined by 508 
quantitative RT-PCR on treated A549 cells. The expression of SPDEF was relative to GAPDH 509 
and normalized to mock treated cells (left panel), or normalized to ZF-NOED (middle and 510 
right panels) to enlarge any difference between wild type and mutant effectors. Dot plots 511 
represent the mean and variation of at least three independent experiments. Statistical 512 
significance was analyzed using one-way ANOVA followed by Bonferroni’s Multiple 513 
Comparison Test (*P<0.05, **P<0.01, ***P<0.001, compared to empty vector; #P<0.05, 514 
##P<0.01, ###P<0.001, compared between two indicated columns). 515 
Figure 7 Expression of ZF-ED after A549 cells treated with ZF fused to different effector 516 
domain (SKD, DNMT3A, G9a, and respective mutant DNMT3A E74A and G9a W1050A). The 517 
expression of ZF-ED was represented as the FLAG-tag expression relative to GAPDH (A), and 518 
normalized to ZF-NOED (B and C). Dot plots represent the mean and variation of three 519 
independent experiments. Statistical significance was analyzed using one-way ANOVA 520 
followed by Bonferroni’s Multiple Comparison Test (#P<0.05, ##P<0.01, ###P<0.001, 521 
compared between two indicated columns).  522 
Figure 8 Quantification of the changes of SPDEF protein levels in A549 cells treated with 523 
SPDEF targeted DNMT3A and G9a. A549 cells were treated with ZF fused with different 524 
effector domains (SKD, DNMT3A, G9a, and respective mutant DNMT3A E74A and G9a 525 
W1050A). (A) Protein expression of SPDEF was assessed by Western blot. An anti-GAPDH 526 
antibody was used as a loading control. Blot pictures shown are representative of three 527 
independent experiments. (B) Densitometric values of SPDEF were normalized against the 528 
loading control, GAPDH. The relative level (ratio to mock) of SPDEF was shown with the 529 
average of three independent experiments. Statistical significance was analyzed using one-530 
way ANOVA followed by Bonferroni’s Multiple Comparison Test (*P<0.05, **P<0.01, 531 
compared to empty vector). 532 
Figure 9 Quantification of MUC5AC positive A549 cells after treatment with SPDEF targeted 533 
DNMT3A and G9a. A549 cells were treated with ZFs fused with different effector domains 534 
(SKD, DNMT3A, G9a, and respective mutant DNMT3A E74A and G9a W1050A) and grown on 535 
coverslips. Immunochemistry staining for MUC5AC was quantified to negative, weak-536 
positive and strong-positive in a blinded fashion. (A) Percentage of MUC5AC positive cells in 537 
the total cell populations. (B) Percentage of MUC5AC strong-positive cells in the total cell 538 
populations. Results are represented as mean and variation of three independent 539 
experiments. Statistical significance was analyzed using one-way ANOVA followed by 540 
Bonferroni’s Multiple Comparison Test (*P<0.05, compared to empty vector).  541 
Figure 10 Expression of irrelevant genes after A549 cells treated with ZF fused to different 542 
effector domain (DNMT3A, G9a, and respective mutant DNMT3A E74A and G9a W1050A). 543 
The expression of PLOD2 (A), TP53 (B), RELA (C) and CDKN1A (D) was relative to ACTB. The 544 
dot plots represent the mean and variation of three independent experiments.  545 
Figure 11 Sustained gene repression by means of epigenetic editing using the CRISPR-dCas9 546 
system. (A) Schematic representation of the experimental setup with the stable MCF7 cells. 547 
mRNA level of SPDEF determined by quantitative RT-PCR on MCF7 stable cells with dCas9- 548 
(B) SKD, (C) G9a and its mutant and Suv39h1 (D) SET and its mutant and (E) DNMT3a3L and 549 
its mutant. Results are represented as average (±SEM) of three independent experiments. 550 
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